News Articles and Montana BioScience Alliance Newsletters


National Institutes of Health — Rocky Mountain Laboratories
May 21, 2024

NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.

Golden Helix, Inc., a leading provider of clinical bioinformatics solutions, is pleased to announce that it has received CE mark approval for its genetic analysis platform VarSeq Suite. This significant regulatory milestone paves the way for the expansion of Golden Helix’s advanced genetic analytics products to the European market, ensuring compliance with the European Union’s health, safety, and environmental protection standards.

National Institutes of Health — Rocky Mountain Laboratories
May 17, 2024

A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people.

Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, has announced the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis. 

A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases.  Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in […]


Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology  that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.

Doctors have told health services to prepare for a new era of cancer screening after a study found a simple blood test could spot multiple cancer types in patients before they develop clear symptoms.

It’s been 60 years since President Kennedy delivered his iconic moonshot speech, marking a goal for America to launch a man into space to step foot on the moon, and bring him back to Earth. On Sept. 12, President Biden gave a speech at the Kennedy Presidential Library in Boston, outlining the progress on his own self-described moonshot: ending cancer.

The National Institute on Aging (NIA) offers early-stage funding opportunities to small businesses and researchers looking to commercialize innovative treatments or technologies to help people enjoy healthier lives as they age. The NIA Small Business Program is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is September 6, 2022. 

The federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs offer a lifeline to small medical technology companies that otherwise would not be able to secure the initial funding necessary for expensive research and development.


May 7, 2024

View the Spring 2024 Newsletter now!

February 20, 2024

View the Winter II 2024 Newsletter now!